Ling W Li

US Patent:

7226951, Jun 5, 2007

Filed:

Dec 16, 2004

Appl. No.:

11/014460

Inventors:

Jayasree Vasudevan - Anaheim CA, US
Liming Wang - Irvine CA, US
Xiaoxia Liu - Tustin CA, US
Kwok Yin Tsang - Irvine CA, US
Ling Li - Irvine CA, US
Janet A. Takeuchi - Anaheim CA, US
Thong Vu - Garden Grove CA, US
Richard Beard - Newport Beach CA, US
Smita Bhat - Irvine CA, US
Vidyasagar Vuligonda - Irvine CA, US
Roshantha A. Chandraratna - Laguna Hills CA, US

Assignee:

Allergan, Inc. - Irvine CA

International Classification:

A61K 31/135
C07C 62/00
C07C 69/52
C07C 211/16

US Classification:

514654, 562500, 564384

Abstract:

Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.

US Patent:

7468391, Dec 23, 2008

Filed:

Dec 13, 2004

Appl. No.:

11/010953

Inventors:

Jayasree Vasudevan - Anaheim CA, US
Rong Yang - Viejo CA, US
Liming Wang - Irvine CA, US
Xiaoxia Liu - Nashua NH, US
Ling Li - Irvine CA, US
Janet Takeuchi - Anaheim CA, US
Thong Vu - Garden Grove CA, US
Richard Beard - Newport Beach CA, US
Smita Bhat - Irvine CA, US
Roshantha A. Chandraratna - Laguna Hills CA, US

Assignee:

Allergan, Inc. - Irvine CA

International Classification:

A01N 31/00
A61K 9/00
A61K 31/415
A61K 9/20
A61K 9/48

US Classification:

514567, 424400, 424404

Abstract:

The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.

US Patent:

7638648, Dec 29, 2009

Filed:

Mar 23, 2007

Appl. No.:

11/728313

Inventors:

Jayasree Vasudevan - Anaheim CA, US
Liming Wang - Irvine CA, US
Xiaoxia Liu - Tustin CA, US
Kwok Yin Tsang - Irvine CA, US
Ling Li - Irvine CA, US
Janet A. Takeuchi - Anaheim CA, US
Thong Vu - Garden Grove CA, US
Richard Beard - Newport Beach CA, US
Smita Bhat - Irvine CA, US
Vidyasagar Vuligonda - Irvine CA, US
Roshantha A. Chandraratna - Laguna Hills CA, US

Assignee:

Allergan Inc. - Irvine CA

International Classification:

C07D 265/06
C07D 263/02
C07D 277/02
C07D 213/02
C07D 333/04
C07D 307/34
C07C 229/34

US Classification:

562433, 562442, 562452, 562488, 562492, 549332, 549398, 549405, 549408, 549429, 548146, 548206, 548215, 548240, 546329

Abstract:

Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.

US Patent:

7754718, Jul 13, 2010

Filed:

May 2, 2005

Appl. No.:

11/579284

Inventors:

Hosup Yeo - Daegu, KR
David J. Austin - New York NY, US
Ling Li - Bellaire TX, US
Yung-chi Cheng - Woodbridge CT, US

Assignee:

Yale University - New Haven CT

International Classification:

A61K 31/502
C07D 237/26

US Classification:

514248, 544233

Abstract:

The present invention relates to novel antiviral helioxanthin analogs. These compounds may particularly be used alone or in combination with other drugs for the treatment of the following: hepadnaviruses, flaviviruses, herpesviruses and human immunodeficiency virus. In addition, compounds according to the present invention can be used to prevent or reduce the likelihood of the occurrence of tumors secondary to virus infection as well as other infections or disease states that are secondary to the virus infection.

US Patent:

8080570, Dec 20, 2011

Filed:

May 1, 2009

Appl. No.:

12/433953

Inventors:

Janet A. Takeuchi - Anaheim CA, US
Ken Chow - Newport Coast CA, US
Ling Li - Irvine CA, US
Liming Wang - Irvine CA, US

Assignee:

Allergan, Inc. - Irvine CA

International Classification:

A01N 43/76
A61K 31/42
C07D 413/00
C07D 263/00

US Classification:

514377, 548233

Abstract:

Described herein are compounds that can be useful as bioactive agents. More specifically, the compounds described herein can be useful as both αand αadrenergic agonists. Methods of synthesis and administration of the compounds are also disclosed.

US Patent:

8273776, Sep 25, 2012

Filed:

Apr 13, 2011

Appl. No.:

13/086071

Inventors:

Janet A. Takeuchi - Anaheim CA, US
Ken Chow - Newport Coast CA, US
Ling Li - Irvine CA, US

Assignee:

Allergan, Inc - Irvine CA

International Classification:

A61K 31/4245
C07D 271/06

US Classification:

514364, 548131

Abstract:

The present invention relates to novel biphenyl oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

US Patent:

8318783, Nov 27, 2012

Filed:

Apr 13, 2011

Appl. No.:

13/085868

Inventors:

Janet A. Takeuchi - Anaheim CA, US
Ken Chow - Newport Coast CA, US
Ling Li - Irvine CA, US

Assignee:

Allergan, Inc. - Irvine CA

International Classification:

A61K 31/4245
C07D 413/10

US Classification:

514364, 548131

Abstract:

Substituted 3-(4-((1H-imidazol-1-yl)methyl)phenyl)-5-phenyl-1,2,4-oxadiazole derivatives which are useful as sphingosine-1-phosphate modulators and useful for treating a wide variety of disorders associated with modulation of sphingosine-1-phosphate receptors.

US Patent:

8362022, Jan 29, 2013

Filed:

Jan 14, 2009

Appl. No.:

12/811773

Inventors:

Todd M. Heidelbaugh - Fountain Valley CA, US
Ken Chow - Newport Coast CA, US
Santosh C. Sinha - Ladera Ranch CA, US
Phong X. Nguyen - Placentia CA, US
Wenkui K. Fang - Irvine CA, US
Ling Li - Irvine CA, US
Janet A. Takeuchi - Anaheim CA, US
Smita S. Bhat - Irvine CA, US

Assignee:

Allergan, Inc. - Irvine CA

International Classification:

A61K 31/497
A61K 31/4439

US Classification:

51425505, 514341, 544336, 5462747

Abstract:

The invention provides well-defined heterocyclic compounds that are useful as subtype selective alpha 2 adrenergic agonists. As such, the compounds described herein, having the structure:.